cyrilzakka/clinical-trials huggingface dataset:
Standardizing Educational Opportunities on the Complete Pediatric Physical Exam

The study proposes that a workshop-based educational experience which utilizes a standardized preceptor training session, a standard skills assessment checklist, and videotaped feedback will improve student comfort and confidence in performing the pediatric physical examination and will provide information to improve the curriculum offerings.

The baseline clinical experience of third year medical students rotating through the clerkship varies, depending on previous clerkships and volunteer opportunities previously encountered. The less experienced third year medical student may require more time and feedback to develop competency. The availability and experience of clinical preceptors and background of the patient may also play a role in the development of pediatric physical examination skills. Other institutions have offered standardized approaches to teaching the health maintenance physical exam. To address these issues, we propose a workshop-based educational experience to (1)determine whether offering a workshop that standardizes exposure to physical exams for junior medical students will improve opportunities to practice physical exam skills in a non-threatening environment, (2)promote immediate feedback to the student that allows for self-reflection by viewing a videotape of their performance, (3)delineate how physical exam skills change in junior medical students throughout the year, and (4)evaluate the inter-rater variability of preceptors teaching health maintenance exams to students rotating through the pediatric clerkship.

Eligibility Criteria:
Inclusion Criteria:

* third year medical students will participate in the physical exam skills workshop as a requirement of their pediatric clerkship; data obtained from review of videotapes of students who consent for data use will be included

Exclusion Criteria:

* data from students who do not consent to use of data will not be used for analysis
A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis

The purpose of this two-center study is to examine the effectiveness of acupuncture treatments in addressing mobility deficits, sensorimotor impairment, and quality of life (QOL) limitations in persons with Multiple Sclerosis (MS). It is hypothesized that acupuncture will result in an improvement in these limitations.

This research study will examine the effects of acupuncture on various symptoms experienced by persons with MS. Persons with MS often use acupuncture as a way of controlling the symptoms of the disease. However, there is little research on whether or not acupuncture has any effect on MS symptoms related to movement. This study intends to look at the effects of acupuncture treatment on walking, balance, and mood in persons with MS.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of MS
* ability to walk unaided for 6 minutes with or without assistive device

Exclusion Criteria:

* bleeding precautions
* trypanophobia
* inability to lie still for 30 minutes
* active cancer, current exacerbation, and history of previous acupuncture treatment
Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment

Pancreatic cancer is a disease with a very poor prognosis and less than 10% of these patients live beyond 5 years from diagnosis. Further, it is expected to become the second leading cause of death in the coming years. Today, surgery remains the cornerstone in curing this disease, but the addition of chemotherapy is needed to improve survival. The impact of adjuvant treatment has been previously demonstrated and its efficacy is absolute. However, neoadjuvant chemotherapy (pre-surgery) improves the results after surgery (achieving earlier stages and with better prognosis) and would lead to better survival results. Besides, the moment of cancer diagnosis is a moment of special receptivity to change lifestyles ("teachable moment").

Multimodal prehabilitation includes 1) physical exercise; 2) nutritional and 3) psychological support. The potential advantages of prehabilitation during neoadjuvant therapy would be 1) the possibility of achieving a better physical condition to face surgery; 2) fewer postoperative complications; 3) more likely to receive adjuvant treatment after surgery; 4) better physical function at the end of treatments. To date, most studies have focused on lung and prostate cancer, with a high prevalence of men in the series.

This strategy has previously been explored, showing that it is safe and feasible, (Loughney et al). We have not identified any study of trimodal prehabilitation during neoadjuvant treatment and none that has integrated motivational strategies to maintain adherence.

Patients during chemotherapy have perceived several adverse effects that could limit adherence to the program. In this regard, a review on the motivation and exercise in cancer survivors shows that it is necessary to apply theoretical frameworks to understand cognitive and motivational processes and develop educational interventions. The self-determination theory is one of the motivational theories most applied today to the analysis of factors related to the adoption of healthy lifestyles. Likewise, patients who are motivated are more likely to improve healthy habits and obtain greater adherence to exercise performance. Therefore, we aimed of carrying out an intervention (pilot study) in ten patients to describe the feasibility of a trimodal prehabilitation program in the hospital environment, applying motivational strategies and a mixed-method (face-to-face and online).

outcome measures refer to feasibility of the intervention:

Recruitment Attendance to the training sessions Attendance to psychologist and nutritionist sessions

And also to physical condition Cardiorespiratory fitness Muscular strength Body composition Physical activity Quality of life Fatigue score

Eligibility Criteria:
Inclusion Criteria:

* More than 18 years old
* ECOG 0-2
* Being able to complete the mile-time test
* Stages I-III
* Being able to understand the informed consent
* Pancreatic cancer diagnosed

Exclusion Criteria:

* Metastasic cancer
A Study of the BREAST-Q REACT Tool for People Having Breast Surgery

The researchers are doing this study to find out whether it is practical (feasible) to conduct a larger study looking at the effects of the BREAST-Q Real-time Engagement and Communication Tool (REACT) on people's quality of life, interactions with their doctors, and medical interventions after undergoing routine breast conserving surgery or mastectomy. The BREAST-Q REACT tool shows scores from standard questionnaires completed before and after breast surgery about overall physical wellbeing, arm pain or tightness, the ability to move the arms and perform everyday tasks, and any symptoms related to the arms, and provides feedback including recommendations and detailed information that help explain these scores and guide topics for people and their doctor to discuss.


Eligibility Criteria:
Inclusion Criteria:

* Scheduled to undergo BCS or mastectomy followed by breast reconstruction with tissue expander, autologous tissues, or direct-to-implant, regardless of neoadjuvant chemotherapy or radiation history
* Female sex
* Able to speak and understand English
* ≥18 years of age
* Able to access the patient portal online

Exclusion Criteria:

* Patient is male
* Younger than 18 years of age
* Cannot communicate in English
* Recurrent breast cancer
* Patients without access to the internet.
Effectiveness of Ergonomics Training and Exercise in Esports Players

The aim of this study is to investigate the effectiveness of ergonomics training and exercise in e-sports players.

After detailed information about the study is given to the individuals to be included in the study, individuals who voluntarily agree to participate in the study will sign an informed consent form. Participants will be divided into 2 groups consisting of equal numbers of individuals. The groups were called control group and exercise group. All participants will be given ergonomics training. In addition to the exercise group, exercise training will be given for 8 weeks, 3 days a week and 45 minutes a day. Sociodemographic information form, Arm, Shoulder and Hand Problems Questionnaire (DASH), Neck Disability Questionnaire (NDI), Rapid Upper Extremity Assessment (RULA) and Pittsburgh Sleep Quality Index (PSQI) will be used as evaluation scales. Evaluations will be made at the beginning and end of the study. will be done once.

Eligibility Criteria:
Inclusion Criteria:

* those who signed the voluntary consent form
* Having actively participated in E-sports organizations and tournaments within 16 months
* not having a chronic disease that will affect the musculoskeletal system
* Not having any health problems that prevent him from exercising and not having had a surgical operation in the last 6 months.

Exclusion Criteria:

* Players under 18 years of age
* have a chronic disease that affects the musculoskeletal system
* Having had a surgical operation in the last 6 months that would prevent him from being interested in e-sports games
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy

Children age, 6 months - 18 years, are eligible if they have one of the following categories of thrombotic microangiopathy (TMA):(1) severe D+HUS; (2) non-familial atypical HUS; (3) familial atypical HUS; or (4) TTP

Patients are seen intially and annually thereafter

Biosamples are collected for storage annually.

Eligibility Criteria:
Inclusion Criteria:

* Severe HUS, familial or non-familial atypical HUS, TTP

Exclusion Criteria:

* None
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, aged 18 years and above
* Diagnosis of schizophrenia of paranoid, disorganized, residual, undifferentiated or catatonic subtype
* Predominant negative symptoms
* With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of two antipsychotics)

Exclusion Criteria:

* Evidence that patient has clinically significant, uncontrolled and unstable disorder (e.g. cardiovascular, renal, hepatic disorder)
* Body Mass Index (BMI) of \<17 or \>40 kg/m2
* Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
* A severity score of 3 or greater on the Parkinsonism item of the ESRS-A (Clinical Global Impression, Parkinsonism)
Hyperglycemia and Acute Pancreatitis

The goal of this observational study is to learn about post-acute pancreatitis diabetes mellitus (PPDM-A). The main questions it aims to answer are:

1. What are the clinical characteristics of PPDM-A?
2. What are the related factors for PPDM-A?

All patients with acute pancreatitis have been given standardized treatment for the condition.

The researchers will compare the PPDM-A group with the non-PPDM-A group to find the risk factors for PPDM-A.

Investigators retrospectively collected data from patients with acute pancreatitis (AP) in participating centers between January 2013 and June 2024.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with pancreatitis attending participating centers since January 2013 (patients with clinically reported AP (ICD-10:K85 or related diagnosis));
2. Age between 18 and 80 years;
3. Patients have undergone glucose metabolic tests at least 1 month after discharge from hospital.

Exclusion Criteria:

1. Patients with a history of diabetes mellitus prior to the AP attack;
2. Patients who underwent pancreatic surgery;
3. Patients with hereditary pancreatitis and autoimmune pancreatitis;
4. Patients with missing data regarding age or gender.
Analgesic Effect of Intraoperative Intravenous S-Ketamine During Total Knee Arthroplasty Surgery

Severe acute pain after total knee arthroplasty surgery has multiple implications for hospitals and patients, monopolising resources and affecting the quality of life. S-ketamine inhibits N-methyl-d-aspartate (NMDA) receptor activation and attenuates central sensitization associated with hyperalgesia, opioid tolerance.Therefore, the primary aim of this trial was to investigate whether s-ketamine decreases pain and opioid consumption postoperatively in adult individuals undergoing total knee arthroplasty surgery.

Total knee arthroplasty surgery is considered a cost-effective therapy for end-stage knee osteoarthritis (KOA). With an ageing population and rising rates of obesity in the world, knee joint replacements are estimated to escalate. While joint replacement is a cost effective intervention,approximately 20% of people experience persist pain postoperatively. The surgical injury triggers a myriad of responses in the pain matrix, from sensitization of peripheral and central pain pathways to feelings of fear, anxiety and frustration.

Opioids are effective for acute postoperative pain but have numerous adverse effects. In addition, postoperative opioid treatment may pose a risk of opioid addiction.

Numerous publications state that adjuvant s-ketamine reduces pain and opioid consumption postoperatively . Whether intraoperative intravenous s-ketamine alleviates postoperative acute pain after total knee arthroplasty surgery still unclear . Therefore, a randomized, controlled, clinical study was designed to observed analgesic effect intraoperative intravenous a lower doses of s-ketamine(0.3mg/kg/h) with patients after total knee arthroplasty surgery .

Eligibility Criteria:
Inclusion Criteria:

1. ASA physical statusI-III;
2. Patients understood the study in detail and voluntarily signed the informed consent before the study;
3. Patients to be treated with total knee arthroplasty Surgery under General anesthesia;
4. Elderly patients(≥65y),regardless of gender;
5. Patients can communicate normally;
6. Patients who have no contraindications to drugs such as midazolam,fentanyl,s-ketamine.

7.18 kg/m2 ≤BMI≤30 kg/m2;

Exclusion Criteria:

1. Increased intracranial or intraocular pressure;
2. severe hypertension;
3. unwillingness the study;
4. severe psychiatric disease and mental system diseases;
5. severe respiratory diseases;
6. hyperthyroidism;
7. liver and kidney dysfunction;
8. alcohol or drug abuse;
9. allergy to midazolam,fentanyl,s-ketamine.
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.

Starting on Day 1 and for up to 12 weeks, you will receive Telaprevir (TVR) and Sofosbuvir (SOF).

You will take one (1) 400 mg tablet of SOF and 3 tablets (1125 mg each) of TVR. You should take these together by mouth every morning. You will take another 3 tablets (1125 mg each) of TVR by mouth 12 hours after you take your morning dose.

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide informed consent
* BMI (Body Mass Index) ≥ 18 kg/m2
* HCV RNA quantifiable at screening and \>1,000 IU/ml
* HCV treatment Naïve
* HCV genotype 1
* 7. Confirmation of chronic HCV infection documented by either: A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection

Exclusion Criteria:

* Current or prior history of any of the following:

Clinically-significant illness Cirrhosis 2. Screening ECG with clinically significant abnormalities

1. ALT \> 10 x the upper limit of normal (ULN)
2. AST \> 10 x ULN
3. Direct bilirubin \> 1.5 x ULN
4. Platelets \< 150,000/μL
5. HbA1c \> 7.5%
6. Creatinine clearance (CLcr) \< 60 mL /min, as calculated by the Cockcroft-Gault equation
7. Hemoglobin \< 11 g/dL for female subjects; \< 12 g/dL for male subjects.
8. Albumin \< 3.1 g/dL
9. INR \> 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR 4. Prior exposure to any approved or experimental HCV-specific direct-acting

   5. Pregnant or nursing female or male with pregnant female partner.

   6. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis).

   7. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
Rhomboid Intercostal and Sub-serratus Block

The rhomboid intercostal block (RIB) can provide good analgesia effects after thoracic surgery . The ultrasound-guided RIB is novel analgesic techniques recently described by Elsharkawy et al. . Additionally, the RISS block anesthetizes the lateral cutaneous branches of the thoracic intercostal nerves and can be used in multiple clinical settings for chest wall and upper abdominal analgesia. However, the analgesic effects of the RISS block after breast surgery have not been analyzed through a randomized-controlled trial.


Eligibility Criteria:
Inclusion criteria Adult patients between 18-50 years. ASA physical status I and II Male gender

Exclusion criteria Patient refusal Contraindications to regional anesthesia Known allergy to local anesthetics Bleeding disorders Use of any anti-coagulants Inability to provide informed consent ASA III-IV

-
Exploring the Feasibility of Social Skills Training in People With Psychosis

Reduced social and community functioning is a predominant and enduring feature in people experiencing severe mental illness such as psychosis. The large majority of interventions (mostly pharmacological) target the so called positive symptoms (e.g. hallucinations and delusions) but poorly address functional and social consequences of the illness.

This study attempts to fill this gap by assessing the feasibility and acceptability of a psychological intervention targeting social cognition deficit in people with psychosis. The intervention is a group psychological treatment facilitated by a clinical psychologist targeting competencies such as emotion recognition, social situation appraisal and guessing people's intentions and mental states. The group therapy takes advantage of audiovisual material to illustrate strategies and thinking styles that may help participants to overcome difficulties in social settings.

A second objective of this study is to test a new method to measure social cognition. Recent research showed that interview and performance based tests are poorly associated with every day activity of people with schizophrenia. This study is planning to evaluate the feasibility of new assessment methods for social cognition in everyday life using portable electronic devices (Experience Sampling Method and an activity watch). These devices will be carried by participants in their everyday life and will ask about feelings and levels of social activities at random times and record basic physiological and activity levels.


Eligibility Criteria:
Inclusion Criteria:

Diagnosis part of the psychosis spectrum (according to DSM-IV or DSM-V or ICD-10); age 18-65 yrs; good command of the English language; social engagement problems as evidenced by care coordinator report and number of hours spent in social activities per week lower than 10.

Exclusion Criteria:

Primary diagnosis of substance abuse disorder; change in antipsychotic medication in the last six weeks; significant learning difficulties (premorbid IQ lower than 70).
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by stereotactic radiosurgery in treating patients who have brain metastases from malignant melanoma.

OBJECTIVES: I. Estimate the 6 month intracranial progression rate and 6 month overall survival rate in patients with limited brain metastases from malignant melanoma undergoing whole brain radiotherapy followed by stereotactic radiosurgery boost. II. Evaluate the qualitative and quantitative toxic effects of this regimen in these patients.

OUTLINE: Patients undergo whole brain radiotherapy 5 days a week for 3 weeks, followed 3-5 weeks later by stereotactic radiosurgery. Patients are followed every 3 months until death.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 2 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven malignant melanoma at primary or any metastatic site Bidimensionally measurable disease by MRI scan Must have 1-6 enhancing brain metastases If at least 2 lesions are present, only 1 lesion may be greater than 3 cm in maximum diameter

PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic response modifier or immunotherapy Chemotherapy: No concurrent chemotherapy with whole brain radiotherapy Prior systemic chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior stereotactic or conventional radiotherapy to any field of the brain Surgery: Prior surgical resection of brain metastases allowed (provided 1 or 2 measurable brain metastases remain)
Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy

The purpose of this study is to investigate and compare the postoperative quality of recovery between the deep neuromuscular blockade and moderate neuromuscular blockade during robotic gastrectomy.


Eligibility Criteria:
Inclusion Criteria:

* adult patients aged 19-80 years who are scheduled for robotic gastrectomy

Exclusion Criteria:

* Neuromuscular disease
* History of malignant hyperthermia
* Significant renal or hepatic dysfunction
* Allergy to sugammadex or rocuronium